Aquestive Therapeutics (AQST) Total Debt (2017 - 2025)
Historic Total Debt for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $36.3 million.
- Aquestive Therapeutics' Total Debt rose 1595.05% to $36.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.3 million, marking a year-over-year increase of 1595.05%. This contributed to the annual value of $32.5 million for FY2024, which is 1814.75% up from last year.
- According to the latest figures from Q3 2025, Aquestive Therapeutics' Total Debt is $36.3 million, which was up 1595.05% from $35.0 million recorded in Q2 2025.
- Aquestive Therapeutics' Total Debt's 5-year high stood at $54.2 million during Q1 2022, with a 5-year trough of $27.5 million in Q4 2023.
- Over the past 5 years, Aquestive Therapeutics' median Total Debt value was $39.2 million (recorded in 2023), while the average stood at $40.0 million.
- As far as peak fluctuations go, Aquestive Therapeutics' Total Debt surged by 4517.67% in 2021, and later crashed by 4720.79% in 2023.
- Quarter analysis of 5 years shows Aquestive Therapeutics' Total Debt stood at $53.6 million in 2021, then fell by 2.67% to $52.1 million in 2022, then tumbled by 47.21% to $27.5 million in 2023, then increased by 18.15% to $32.5 million in 2024, then grew by 11.5% to $36.3 million in 2025.
- Its Total Debt was $36.3 million in Q3 2025, compared to $35.0 million in Q2 2025 and $33.8 million in Q1 2025.